查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016390

男性性腺功能低下症市場報告：按治療方法、給藥方式、應用和地區分類（2026-2034 年）

Male Hypogonadism Market Report by Therapy Type, Drug Delivery, Application, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球男性性腺功能低下症市場規模達40億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到59億美元，2026年至2034年的複合年成長率為4.14%。市場成長的主要促進因素包括男性睪固酮缺乏症盛行率顯著上升、患者對男性性腺功能低下症症治療方案的認知度提高以及人們健康意識的增強。

男性性腺功能低下症是指睪丸無法產生足夠的睪固酮，導致肌肉生長遲緩不良、體毛過多、乳房發育、聲音低沉。這種疾病的特徵是男性睪固酮或精子生成不足。其原因可能與睪丸疾病（原發性性腺功能減退症）或下視丘-腦下垂體軸疾病（續發性性腺功能減退症）有關。由於此疾病源自於睪丸問題或影響下視丘-腦下垂體的疾病，因此性腺功能減退症患者可能出現各種器官功能障礙，生活品質下降。男性性腺功能減退症可以是遺傳性的，也可以是後天獲得的，原因包括荷爾蒙失衡、藥物或老齡化。有些先天性酵素異常會導致全身不同程度的雄性激素抵抗。性腺功能減退症最常見於60歲以上的男性，其症狀和徵兆隨年齡而變化。

男性性腺功能低下症市場趨勢：

全球市場的主要驅動力是男性睪酮缺乏症盛行率的顯著上升和不孕率的增加。這被認為是由包括肥胖和糖尿病在內的慢性文明病發生率的上升所致。老年人口的成長（他們更容易罹患男性性腺功能低下症）也是推動市場成長的因素之一。此外，患者對男性性腺功能低下症治療方案的認知度提高也是重要的成長促進因素。許多國家的政府機構正在進行關於性腺功能減退症治療方法（包括睾酮替代療法）的宣傳活動。然而，局部注射睪固酮的嚴重副作用是男性性腺功能低下症市場成長的一大障礙。另一方面，臨床試驗的增加和新治療方法的出現預計將在預測期內為男性性腺功能低下症市場創造新的成長機會。此外，全球醫療保健基礎設施的持續技術進步也為市場帶來了良好的前景。其他促進市場擴張的因素包括快速的都市化、健康意識的提高、醫療成本的上升以及積極的研發活動。

本報告解答的主要問題

  • 全球男性性腺功能低下症市場迄今的發展軌跡如何？未來幾年我們可以預期哪些趨勢？
  • 全球男性性腺功能低下症的促進因素、阻礙因素和機會是什麼？
  • 主要區域市場有哪些？
  • 哪個國家男性性腺功能低下症市場最具吸引力？
  • 市場如何依治療方法細分？
  • 依給藥方式分類的市場區隔如何？
  • 按應用領域分類的市場區隔如何？
  • 全球男性性腺功能低下症市場的競爭格局如何？
  • 全球男性性腺功能低下症市場的主要參與者/公司有哪些？

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：男性性腺功能低下症的全球市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依治療方法分類

  • 睾酮替代療法
  • 促性腺激素分泌釋放荷爾蒙療法

第7章 市場區隔：依藥物輸送服務分類

  • 外用凝膠
  • 注射藥物
  • 經皮吸收貼片
  • 其他

第8章 市場區隔：依應用領域分類

  • 卡門氏症候群
  • 柯林菲特氏症
  • 腦下垂體疾病
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章：促進、抑制與機遇

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • AbbVie Inc
    • Endo International Plc
    • Ferring Holding SA
    • Grunenthal GmbH
    • Lilly USA, LLC（Eli Lilly and Company）
    • Pfizer Inc
    • Sun Pharmaceutical Industries Limited
    • Teva Pharmaceutical Industries Ltd
Product Code: SR112026A7206

The global male hypogonadism market size reached USD 4.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 5.9 Billion by 2034, exhibiting a growth rate (CAGR) of 4.14% during 2026-2034. A considerable rise in the prevalence of testosterone deficiency in males, the rising awareness of male hypogonadism treatment choices among the patient population, and increasing health consciousness represent some of the key factors driving the market.

Male hypogonadism is a medical condition in which the testes fail to produce enough testosterone, leading to a lack of muscle growth, impaired hair growth, breast development, as well as a lack of deepening of the voice. The medical condition is characterized by a lack of testosterone or spermatozoa production in men. It is caused owing to the disorder related to the testes (primary hypogonadism) or the hypothalamic-pituitary axis (secondary hypogonadism). An individual with hypogonadism may suffer from a variety of organ dysfunctions as well as a reduction in quality of life since it originates from a testicular problem or disorder that affects the hypothalamus and pituitary gland. Hypogonadism in men can be genetic or acquired, caused by hormonal imbalances, medications or aging. Several congenital enzyme abnormalities are responsible for causing different degrees of androgen resistance throughout the body. Hypogonadism is most common in men over the age of 60, and the symptoms and indications of the deficiency vary accordingly.

MALE HYPOGONADISM MARKET TRENDS:

The global market is primarily driven by a considerable rise in the prevalence of testosterone deficiency in males, along with the growing infertility rates. This can be attributed to the increasing incidences of chronic lifestyle disorders, including obesity and diabetes. In line with this, the expanding geriatric population that is more susceptible to developing male hypogonadism is also providing an impetus to the market. Moreover, the rising awareness of male hypogonadism treatment choices among the patient population is also acting as a significant growth-inducing factor. Government bodies across several countries are promoting awareness of hypogonadism treatment methods, including testosterone replacement therapy (TST). However, severe adverse reactions associated with external testosterone hormone injections are acting as a significant growth-restraining factor for the male hypogonadism market. Conversely, the increasing number of clinical trials and the emergence of new treatment options are expected to create new male hypogonadism market opportunities for growth during the forecast period. Apart from this, continual technological advancements in the development of medical infrastructure on the global level are creating a positive outlook for the market. Some of the other factors contributing to the market include rapid urbanization, increasing health consciousness, high medical expenditure and extensive research and development (R&D) activities.

KEY MARKET SEGMENTATION:

Therapy Type Insights

  • Testosterone Replacement Therapy
  • Gonadotropin-Releasing Hormones Therapy

Drug Delivery Insights

  • Topical Gels
  • Injectables
  • Transdermal Patches
  • Others

Application Insights

  • Kallmann Syndrome
  • Klinefelters Syndrome
  • Pituitary Disorders
  • Others

Regional Insights

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for male hypogonadism. Some of the factors driving the North America male hypogonadism market include the growing geriatric population, rising prevalence of sedentary lifestyle and related medical conditions, increasing number of clinical trials, the emergence of new treatment options, etc.

COMPETITIVE LANDSCAPE:

The report has also provided a comprehensive analysis of the competitive landscape in the global male hypogonadism market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AbbVie Inc, Endo International Plc, Ferring Holding S.A, Grunenthal GmbH, Lilly USA, LLC (Eli Lilly and Company), Pfizer Inc, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How has the global male hypogonadism market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global male hypogonadism market?
  • What are the key regional markets?
  • Which countries represent the most attractive male hypogonadism markets?
  • What is the breakup of the market based on the therapy type?
  • What is the breakup of the market based on the drug delivery?
  • What is the breakup of the market based on the application?
  • What is the competitive structure of the global male hypogonadism market?
  • Who are the key players/companies in the global male hypogonadism market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Male Hypogonadism Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy Type

  • 6.1 Testosterone Replacement Therapy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Gonadotropin-Releasing Hormones Therapy
    • 6.2.1 Market Trends
    • 6.2.3 Market Forecast

7 Market Breakup by Drug Delivery

  • 7.1 Topical Gels
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Injectables
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Transdermal Patches
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Kallmann Syndrome
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Klinefelters Syndrome
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Pituitary Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Endo International Plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Ferring Holding S.A
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Grunenthal GmbH
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 SWOT Analysis
    • 14.3.5 Lilly USA, LLC (Eli Lilly and Company)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Pfizer Inc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Sun Pharmaceutical Industries Limited
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Teva Pharmaceutical Industries Ltd
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio

List of Figures

  • Figure 1: Global: Male Hypogonadism Market: Major Drivers and Challenges
  • Figure 2: Global: Male Hypogonadism Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Male Hypogonadism Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Male Hypogonadism Market: Breakup by Therapy Type (in %), 2025
  • Figure 5: Global: Male Hypogonadism Market: Breakup by Drug Delivery (in %), 2025
  • Figure 6: Global: Male Hypogonadism Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Male Hypogonadism Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Male Hypogonadism (Testosterone Replacement Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Male Hypogonadism (Testosterone Replacement Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Male Hypogonadism (Gonadotropin-Releasing Hormones Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Male Hypogonadism (Gonadotropin-Releasing Hormones Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Male Hypogonadism (Topical Gels) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Male Hypogonadism (Topical Gels) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Male Hypogonadism (Injectables) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Male Hypogonadism (Injectables) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Male Hypogonadism (Transdermal Patches) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Male Hypogonadism (Transdermal Patches) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Male Hypogonadism (Other Drug Deliveries) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Male Hypogonadism (Other Drug Deliveries) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Male Hypogonadism (Kallmann Syndrome) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Male Hypogonadism (Kallmann Syndrome) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Male Hypogonadism (Klinefelters Syndrome) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Male Hypogonadism (Klinefelters Syndrome) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Male Hypogonadism (Pituitary Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Male Hypogonadism (Pituitary Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Male Hypogonadism (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Male Hypogonadism (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: North America: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: North America: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: United States: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: United States: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Canada: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Canada: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Asia-Pacific: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Asia-Pacific: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: China: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: China: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Japan: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Japan: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: India: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: India: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: South Korea: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: South Korea: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Australia: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Australia: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Indonesia: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Indonesia: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Others: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Others: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Europe: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Europe: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Germany: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Germany: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: France: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: France: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: United Kingdom: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: United Kingdom: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Italy: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Italy: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Spain: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Spain: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Russia: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Russia: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Others: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Others: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Latin America: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Latin America: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Brazil: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Brazil: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Mexico: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Mexico: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Others: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Others: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Middle East and Africa: Male Hypogonadism Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Middle East and Africa: Male Hypogonadism Market: Breakup by Country (in %), 2025
  • Figure 76: Middle East and Africa: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Global: Male Hypogonadism Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Male Hypogonadism Industry: Value Chain Analysis
  • Figure 79: Global: Male Hypogonadism Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Male Hypogonadism Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Male Hypogonadism Market Forecast: Breakup by Therapy Type (in Million USD), 2026-2034
  • Table 3: Global: Male Hypogonadism Market Forecast: Breakup by Drug Delivery (in Million USD), 2026-2034
  • Table 4: Global: Male Hypogonadism Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Male Hypogonadism Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Male Hypogonadism Market: Competitive Structure
  • Table 7: Global: Male Hypogonadism Market: Key Players